Compare Abbott Laboratories (ABT) vs Fox Corp Class A (FOXA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Fox Corp Class A — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Fox Corp Class A trades at $53.29 (market cap $21.80B). The key difference: Abbott Laboratories is far larger — about 7.7× Fox Corp Class A's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | FOXA | |
|---|---|---|
Market Cap | $166.94B | $21.80B |
Sector | Health | Media |
52-Week High | $136.62 | $76.11 |
52-Week Low | $82.57 | $48.79 |
Enterprise Value | $193.69B | $25.77B |
Dividend Yield | 2.63% | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
FOXA trades at $55.87, down 1.08% with bearish technical signals despite strong fundamentals. The company reported robust earnings with Q1 2026 EPS of $1.32 beating expectations by 29%, continuing a trend of quarterly beats. Revenue grew to $16.3B in 2025 with net income margin expanding to 13.88%. However, the stock faces headwinds from the recent $22B Roku acquisition announcement, which has raised leverage concerns and contributed to recent price weakness.
The outlook remains balanced with 50% analyst buy ratings and a $67.80 consensus target suggesting 21% upside potential. Key risks include integration challenges from the Roku acquisition and streaming competition, while opportunities lie in advertising growth from World Cup events and Tubi streaming momentum. Valuation appears reasonable with P/E of 14.7x and EV/EBITDA of 8.4x.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →
